CD3E and acute myeloid leukemia: A recent phase I/II study using flotetuzumab (anti-CD3ε × anti-CD123) in 88 adults with relapsed/refractory AML with primary induction failure and relapse after <6 months showed an acceptable safety profile and encouraging evidence of clinical activity (15).